HIGHLIGHTS
- who: Di Zhu and collaborators from the Shanghai Jiao Tong University, China have published the research work: Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study, in the Journal: (JOURNAL)
- what: The study was approved by the Institutional Ethics Review Boards of both hospitals, and the procedures followed in this study were conducted in accordance with the guidelines of the World Medical Association Declaration of Helsinki. This study showed that TACE combined with apatinib and camrelizumab therapy demonstrated superior efficacy to TACE combined with apatinib . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.